Walsh & Associates’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$60.2K Buy
52
+7
+16% +$8.26K 0.05% 111
2026
Q2
$54K Sell
45
-1
-2% -$1.02K 0.04% 114
2026
Q1
$42.3K Buy
46
+1
+2% +$1.01K 0.04% 122
2025
Q4
$48.4K Hold
45
– – 0.05% 112

Other funds holding LLY

Walsh & Associates's LLY Position: Q3 2026 in Review

Walsh & Associates increased its Eli Lilly (LLY) stake by 16% in Q3 2026, buying an estimated $8.26K and bringing the position to 52 shares worth $60.2K. The position accounts for 0.05% of the portfolio, ranked #111.

Walsh & Associates first reported a position in LLY in Q4 2025 and has held it in 4 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Walsh & Associates held 52 shares of Eli Lilly worth $60.2K as of Q3 2026.
  • Walsh & Associates bought 7 Eli Lilly shares in Q3 2026, an estimated $8.26K.
  • Eli Lilly made up 0.05% of Walsh & Associates's portfolio in Q3 2026, its #111 holding.
  • Walsh & Associates first reported a position in Eli Lilly in Q4 2025 and has held it in 4 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Walsh & Associates's 13F filing for Q3 2026, filed 9 Nov 2026.